May 19, 2021 Acad, Gov/Utilities Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific and University of California, San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center

Thermo Fisher Scientific and University of California, San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center New facility will provide end-to-end solution to accelerate cell therapy development and manufacturing WALTHAM, Mass. and SAN FRANCISCO, May 19, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and the University of... Read more

May 13, 2021 Acad, Gov/Utilities PR/Corporate

Ultra-high-field MRI Combines Forces with Artificial Intelligence: AIR Recon DL receives FDA 510(k) clearance on SIGNA 7.0T

Industry-first, deep learning image reconstruction technology, AIR Recon DL, now available on entire GE MR portfolio, including SIGNA 7.0T scanner Waukesha, WI – May 13, 2021 – Ahead of this year’s virtual ISMRM meeting, GE Healthcare is excited to announce that AIR Recon DL, the industry’s first deep learning image reconstruction technology that works across... Read more

May 12, 2021 Acad, Gov/Utilities M&A, Partnerships

Canada’s FortisBC Energy Selects Xylem for Advanced Gas Network

One million Sonix IQ meters to help increase safety and reliability in 20-year technology and services agreement RYE BROOK, N.Y.–(BUSINESS WIRE)–May 12, 2021– Xylem Inc. (NYSE: XYL), a leading global water and resource management technology company, is working with FortisBC Energy Inc. in British Columbia to deploy a Sensus advanced gas meter network. FortisBC serves... Read more

April 28, 2021 Acad, Gov/Utilities

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for previously untreated metastatic bladder cancer

Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) who are... Read more

April 28, 2021 Acad, Gov/Utilities Environ, Ag./Food & Bev Licensing, IP, and Legal M&A, Partnerships

Xylem, Esri Partnership Pairs Global Leaders In Water Technology And GIS To Help Utilities Worldwide Streamline Data And Insight

Xylem Becomes Platinum Esri Partner, Will Create Joint Solutions, Collaborate On Marketing Water Operators To Benefit From Better Network Visibility, Optimized Infrastructure, Lower Costs RYE BROOK, N.Y.–(BUSINESS WIRE)–Apr. 28, 2021– Xylem (NYSE:XYL), a leading water technology company dedicated to solving the world’s greatest water challenges, has forged a partnership with Esri, the global leader in... Read more

April 28, 2021 Acad, Gov/Utilities Bio/Pharma/CRO Lab Top-10 Licensing, IP, and Legal

Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society

Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society WALTHAM, Mass. (April 28, 2021) — Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval... Read more

April 27, 2021 Acad, Gov/Utilities Licensing, IP, and Legal

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer

Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 2 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally... Read more

April 23, 2021 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. PAI Top-10 PR/Corporate

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

About 90,000 women globally die from endometrial cancer each year1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly) Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a... Read more

April 20, 2021 Acad, Gov/Utilities Environ, Ag./Food & Bev

Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees with the European Commission’s Directorate-General for Competition’s decision to review Illumina’s acquisition of GRAIL, a company founded to accelerate early screening of cancer. Illumina will continue to work with the Directorate-General to bring the investigation to conclusion. Illumina remains committed to the transaction, the... Read more